Provision of Clinical Trial Monitoring to the FaR-RMS Trial

The FaR-RMS trial The University of Birmingham Cancer Research Clinical Trials Unit are working on a collaboration with a large Pharmaceutical company to add a new arm to an existing study. The trial is a multicentre, randomised phase II trial evaluating the new therapy against a control arm in paediatric patients with relapsed/refractory rhabdomyosarcoma. Patients will receive therapy for up to 12 cycles (approx. 12 months) and will be followed-up for 5 years.